MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Regional Innovation Clusters (RICs), Incubators, Accelerators, Technology Transfer, SBIR/STTR, OTA, Non-Traditionals & Triple Helix
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
Cubist Pharmaceuticals, Inc. (CBST)
Finance & Acquisitions: Cubist
Trius Therapeutics (TSRX)
Attachments
Angelcapitalassociation
Parents
*Architects: Infectious Disease _ Bacteriology_Antibiotics
*Industry: San Diego, California
Companies: Acquired_(M&A)
Finance & Acquisitions: Cubist
Children
Biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections
Cubist Buys Trius, Optimer for New Hospital Antibiotics (2013)
San Diego, California
Series B led by Kleiner, Perkins, Caufield and Byers (KPCB), and FinTech Global Capital, Sofinnova Ventures, Versant Ventures, Interwest Partners and Prism VentureWorks.
The company’s first product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by MRSA.
Trius Raises $30 Million in Series B Financing (2008)
Trius Therapeutics Announces Pricing for Initial Public Offering (2010)
Trius Therapeutics Completes $20 Million Series A Financing and Names CEO (2007)
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens.